
    
      The proportion of treatment received during all lines of therapy in the metastatic setting
      will be described. The 2-year survival rate and median OS with interquartile range (IQR) for
      third-line therapy will be calculated. HRU data and costs during third-line therapy will be
      collected.
    
  